Applied therapeutics inc APLT.US 總覽分析
APLT 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
價值面評分低,若以價值投資為目標且有長期投資部位,需要嚴格執行自己的出場計畫來減持部位
APLT 近期報酬表現
15.74%
Applied therapeutics inc
4.57%
同產業平均
3.26%
S&P500
與 APLT 同產業的標的表現
- EPRX Eupraxia pharmaceuticals inc價值 -趨勢 4 分波段 2 分籌碼 -股利 1 分查看更多
APLT 公司資訊
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company's lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company's pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).